CRL Charles River Laboratories
Industrials · Services-Commercial Physical & Biological Research
Charles River Laboratories (CRL) is a industrials company in the Services-Commercial Physical & Biological Research industry, with a market capitalization of $8.9 billion. Shares last traded at $185.09, 19.0% below their 52-week high. Over the past year the stock is up 27.6%. Net profit margin is -3.6%, below the peer median of 8.4%. Revenue declined 0.9% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2025-12-27 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.30 | 2026-05-07 |
| FY 2025 | $-2.91 | 2026-02-18 |
| Q3 2025 | $2.65 | 2025-11-05 |
| Q2 2025 | $1.55 | 2025-08-06 |
| Q1 2026 | $0.50 | 2026-05-07 |
| FY 2025 | $0.20 | 2026-02-18 |
Services-Commercial Physical & Biological Research peers
CRL vs 12 industry peers (Services-Commercial Physical & Biological Research), by market cap.
| IQV | IQVIA | $28.0B | 20.58 | 1.72 | 8.3% | -1.74% |
| INCY | Incyte | $19.6B | 15.26 | 3.82 | 25.0% | -0.73% |
| MEDP | Medpace Holdings, Inc. | $13.1B | 29.14 | 5.19 | 17.8% | +0.66% |
| CRL | Charles River Laboratories | $8.9B | -61.77 | 2.22 | -3.6% | +1.47% |
| ABSI | Absci Corp | $1.2B | -10.00 | — | — | +3.07% |
| NRC | Nrc Health | $418M | 36.04 | 3.04 | 8.4% | +4.57% |
| OABI | OmniAb, Inc. | $339M | -5.24 | — | — | +15.27% |
| MXCT | MAXCYTE, INC. | $129M | -2.88 | — | — | +5.73% |
| ONMD | OneMedNet Corp | $31M | -10.93 | — | — | -5.21% |
| BIAF | bioAffinity Technologies, Inc. | $4M | — | — | — | +0.63% |
| ISPC | iSpecimen Inc. | $4M | -0.36 | — | — | +0.38% |
| ICLR | Icon Plc | — | — | — | 2.8% | +1.94% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.